# Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation

> **NCT05391893** · PHASE4 · COMPLETED · sponsor: **Corewell Health South** · enrollment: 444 (actual)

## Conditions studied

- Atrial Fibrillation
- Atrial Flutter

## Interventions

- **DRUG:** Oral
- **DRUG:** Intravenous drug

## Key facts

- **NCT ID:** NCT05391893
- **Lead sponsor:** Corewell Health South
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-19
- **Primary completion:** 2023-04-01
- **Final completion:** 2023-04-01
- **Target enrollment:** 444 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05391893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05391893, "Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05391893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*